Brentuximab vedotin regimen lowers relapse risk in pediatric high-risk Hodgkin lymphoma

The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results. The findings, published in The New England Journal of Medicine, additionally showed the brentuximab vedotin (Adcetris, Seagen) regimen to be well tolerated.

Related Keywords

Sharonm Castellino ,Catherinem Bollard ,Mark Roschewski ,Blood Disorders Center ,Children Oncology Group ,Emory University School Of Medicine ,National Cancer Trials Network Cooperative Group ,Winship Cancer Institute Of Emory University ,Cancer Research ,Children National Research Institute Center ,Immunology Research ,New England Journal ,Aflac Cancer ,Emory University School ,Winship Cancer Institute ,Emory University ,Oncology Group ,National Cancer Trials Network Cooperative ,National Research Institute ,